Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

…, PH Van Der Graaf, J Arrowsmith, DE Feltner… - Drug discovery today, 2012 - Elsevier
… Author links open overlay panel Paul Morgan 1 , Piet H. Van Der Graaf 1 2 , John Arrowsmith
3 , Doug E. Feltner 4 , Kira S. Drummond 5 , Craig D. … PH Van der Graaf, N. Benson …

[HTML][HTML] Methods of model reduction for large-scale biological systems: a survey of current methods and trends

TJ Snowden, PH van der Graaf, MJ Tindall - Bulletin of mathematical …, 2017 - Springer
Complex models of biochemical reaction systems have become increasingly common in the
systems biology literature. The complexity of such models can present a number of …

Towards a mechanism-based analysis of pharmacodynamic drug–drug interactions in vivo

DM Jonker, SAG Visser, PH Van Der Graaf… - Pharmacology & …, 2005 - Elsevier
The combination of drugs is a common practice for enhancing the efficiency of drug treatment,
but selection of the optimal combination and the optimal doses remains a matter of trial …

Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development

PH Van der Graaf, N Benson - Pharmaceutical research, 2011 - Springer
Mechanistic PKPD models are now advocated not only by academic and industrial
researchers, but also by regulators. A recent development in this area is based on the growing …

The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologics

BM Agoram, SW Martin, PH Van der Graaf - Drug discovery today, 2007 - Elsevier
Lack of predictability of clinical efficacy and safety is an important problem facing pharmaceutical
research today. Translational PK–PD has the ability to integrate data generated from …

In vivo target residence time and kinetic selectivity: the association rate constant as determinant

WEA de Witte, M Danhof, PH van der Graaf… - Trends in …, 2016 - cell.com
It is generally accepted that, in conjunction with pharmacokinetics, the first-order rate constant
of target dissociation is a major determinant of the time course and duration of in vivo …

[HTML][HTML] Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine

I Kohler, T Hankemeier, PH van der Graaf… - European journal of …, 2017 - Elsevier
Novel developments in biomarkers discovery are essential in modern health care, notably
in treatment individualization and precision medicine. Clinical metabolomics, which aims to …

[HTML][HTML] Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy

…, AC Harms, CAJ Knibbe, PH Van der Graaf… - Metabolomics, 2017 - Springer
Personalized medicine, in modern drug therapy, aims at a tailored drug treatment accounting
for inter-individual variations in drug pharmacology to treat individuals effectively and safely…

Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point

…, PG Baverel, A Woodcock, PH Van Der Graaf… - Journal of allergy and …, 2013 - Elsevier
Background Inhaled capsaicin elicits cough reproducibly in human subjects and is widely
used in the study of cough and antitussive therapies. However, the traditional end points C2 …

[HTML][HTML] Design principles of collateral sensitivity-based dosing strategies

…, PH van der Graaf, DE Rozen, JGC van Hasselt - Nature …, 2021 - nature.com
Collateral sensitivity (CS)-based antibiotic treatments, where increased resistance to one
antibiotic leads to increased sensitivity to a second antibiotic, may have the potential to limit the …